JERUSALEM Teva Pharmaceutical Industries and Active Biotech announced promising results from a mid-stage trial of laquinimod, a once-daily oral treatment for relapsing-remitting multiple sclerosis.
The companies released results of a phase-2 extension study of the drug indicating that it was safe for use in patients, but also reduced lesions that are a marker of disease activity by 52%. In addition, the study indicated that the drug reduced relapses of the disease and did not show evidence of suppression of the immune system. Results of the study were published online in the journal Multiple Sclerosis.
The two companies expect to see results of two phase-3 trials of the drug next year. The Food and Drug Administration gave fast-track designation to the drug in February 2009.